Cargando…

Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine

BACKGROUND/AIMS: Diarrhea-predominant irritable bowel syndrome (IBS-D) has been previously associated with evidence of immune activation and altered microbiota. Our aim is to assess the effect of the anti-inflammatory agent, mesalazine, on inflammatory gene expression and microbiota composition in I...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalanka, Jonna, Lam, Ching, Bennett, Andrew, Hartikainen, Anna, Crispie, Fiona, Finnegan, Laura A, Cotter, Paul D, Spiller, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Neurogastroenterology and Motility 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026366/
https://www.ncbi.nlm.nih.gov/pubmed/33795545
http://dx.doi.org/10.5056/jnm20205
_version_ 1783675658498473984
author Jalanka, Jonna
Lam, Ching
Bennett, Andrew
Hartikainen, Anna
Crispie, Fiona
Finnegan, Laura A
Cotter, Paul D
Spiller, Robin
author_facet Jalanka, Jonna
Lam, Ching
Bennett, Andrew
Hartikainen, Anna
Crispie, Fiona
Finnegan, Laura A
Cotter, Paul D
Spiller, Robin
author_sort Jalanka, Jonna
collection PubMed
description BACKGROUND/AIMS: Diarrhea-predominant irritable bowel syndrome (IBS-D) has been previously associated with evidence of immune activation and altered microbiota. Our aim is to assess the effect of the anti-inflammatory agent, mesalazine, on inflammatory gene expression and microbiota composition in IBS-D. METHODS: We studied a subset of patients (n = 43) from a previously published 12-week radomized placebo-controlled trial of mesalazine. Mucosal biopsies were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction for a range of markers of inflammation, altered permeability, and sensory receptors including Toll-like receptors (TLRs) at randomization after treatment. All biopsy data were compared to 21 healthy controls. Patient’s stool microbiota composition was analysed through 16S ribosomal RNA sequencing. RESULTS: We found no evidence of increased immune activation compared to healthy controls. However, we did find increased expression of receptors in both sensory pathways and innate immune response including TLR4. Higher TLR4 expression was associated with greater urgency. TLR4 expression correlated strongly with the expression of the receptors bradykinin receptor B2, chemerin chemokine-like receptor 1, and transient receptor potential cation channel, subfamily A, member 1 as well as TLR4’s downstream adaptor myeloid differentiation factor 88. Mesalazine had minimal effect on either gene expression or microbiota composition. CONCLUSIONS: Biopsies from a well-characterized IBS-D cohort showed no substantial inflammation. Mesalazine has little effect on gene expression and its previous reported effect on fecal microbiota associated with much greater inflammation found in inflammatory bowel diseases is likely secondary to reduced inflammation. Increased expression of TLR4 and correlated receptors in IBS may mediate a general increase in sensitivity to external stimuli, particularly those that signal via the TLR system.
format Online
Article
Text
id pubmed-8026366
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-80263662021-04-30 Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine Jalanka, Jonna Lam, Ching Bennett, Andrew Hartikainen, Anna Crispie, Fiona Finnegan, Laura A Cotter, Paul D Spiller, Robin J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Diarrhea-predominant irritable bowel syndrome (IBS-D) has been previously associated with evidence of immune activation and altered microbiota. Our aim is to assess the effect of the anti-inflammatory agent, mesalazine, on inflammatory gene expression and microbiota composition in IBS-D. METHODS: We studied a subset of patients (n = 43) from a previously published 12-week radomized placebo-controlled trial of mesalazine. Mucosal biopsies were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction for a range of markers of inflammation, altered permeability, and sensory receptors including Toll-like receptors (TLRs) at randomization after treatment. All biopsy data were compared to 21 healthy controls. Patient’s stool microbiota composition was analysed through 16S ribosomal RNA sequencing. RESULTS: We found no evidence of increased immune activation compared to healthy controls. However, we did find increased expression of receptors in both sensory pathways and innate immune response including TLR4. Higher TLR4 expression was associated with greater urgency. TLR4 expression correlated strongly with the expression of the receptors bradykinin receptor B2, chemerin chemokine-like receptor 1, and transient receptor potential cation channel, subfamily A, member 1 as well as TLR4’s downstream adaptor myeloid differentiation factor 88. Mesalazine had minimal effect on either gene expression or microbiota composition. CONCLUSIONS: Biopsies from a well-characterized IBS-D cohort showed no substantial inflammation. Mesalazine has little effect on gene expression and its previous reported effect on fecal microbiota associated with much greater inflammation found in inflammatory bowel diseases is likely secondary to reduced inflammation. Increased expression of TLR4 and correlated receptors in IBS may mediate a general increase in sensitivity to external stimuli, particularly those that signal via the TLR system. The Korean Society of Neurogastroenterology and Motility 2021-04-30 2021-04-30 /pmc/articles/PMC8026366/ /pubmed/33795545 http://dx.doi.org/10.5056/jnm20205 Text en © 2020 The Korean Society of Neurogastroenterology and Motility https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jalanka, Jonna
Lam, Ching
Bennett, Andrew
Hartikainen, Anna
Crispie, Fiona
Finnegan, Laura A
Cotter, Paul D
Spiller, Robin
Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
title Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
title_full Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
title_fullStr Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
title_full_unstemmed Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
title_short Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine
title_sort colonic gene expression and fecal microbiota in diarrhea-predominant irritable bowel syndrome: increased toll-like receptor 4 but minimal inflammation and no response to mesalazine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026366/
https://www.ncbi.nlm.nih.gov/pubmed/33795545
http://dx.doi.org/10.5056/jnm20205
work_keys_str_mv AT jalankajonna colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT lamching colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT bennettandrew colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT hartikainenanna colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT crispiefiona colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT finneganlauraa colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT cotterpauld colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine
AT spillerrobin colonicgeneexpressionandfecalmicrobiotaindiarrheapredominantirritablebowelsyndromeincreasedtolllikereceptor4butminimalinflammationandnoresponsetomesalazine